An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma.

Trial Profile

An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2015

At a glance

  • Drugs Sotrastaurin (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 11 Sep 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 30 Jan 2014 Status changed from recruiting to discontinued, as reported by M.D. Anderson Cancer Center record.
    • 17 May 2013 Planned end date changed from 1 Jan 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top